Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release

The European Journal of Neuroscience
B MarcosM J Ramirez


The involvement of the cholinergic system in learning and memory together with the cognitive enhancing properties of 5-HT6 receptor antagonists led us to study the relationship between 5-HT6 receptors and cholinergic neurotransmission. A selective cholinergic lesion, induced by injection of the immunotoxin 192-IgG-Saporin into the nucleus basalis magnocellularis, failed to alter the density of 5-HT6 receptor mRNA or protein expression in the deafferentated frontal cortex, suggesting that 5-HT6 receptors are not located on cholinergic neurons. The 5-HT6 receptor antagonist SB-357134 (0.001-1 microM) induced a concentration-dependant K+-evoked [3H]acetylcholine (ACh) release in vitro in rat cortical and striatal slices, which was blocked by tetrodotoxin. SB-357134, up to 1 microM, stimulated glutamate release in cortical and striatal slices. In the cortex, riluzole (1 microM) blocked the SB-357134-induced K+-stimulated [3H]ACh release, and simultaneous administration of MK-801 (1 microM) and SB-357134 (0.05 microM) elicited an increase in K+-evoked ACh release. In the striatum, SB-357134, 1 microM, decreased dopamine release, and the increase in K+-evoked [3H]ACh release induced by 5-HT6 receptor blockade was reversed by the D1 r...Continue Reading


Jul 16, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Neil UptonDavid J Virley
Jan 22, 2013·ACS Chemical Neuroscience·Susanna LyBernat Kocsis
Jul 4, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Virginie Da Silva CostaFrançois Dauphin
Jan 17, 2014·Experimental Brain Research·Mohammad SeyedabadiReza Rahimian
Nov 10, 2015·Expert Opinion on Investigational Drugs·Karsten WickeAnton Bespalov
Feb 17, 2010·Neuropharmacology·Paul T FrancisMitchell K Lai
Sep 8, 2009·Neurobiology of Learning and Memory·A Huerta-RivasAlfredo Meneses
Apr 30, 2010·The International Journal of Neuropsychopharmacology·Marcel M van GaalenTaco J De Vries
Sep 10, 2009·The International Journal of Neuropsychopharmacology·B MarcosM J Ramirez
Jun 8, 2011·Behavioural Brain Research·Simona ScheggiMaria Graziella De Montis
Jun 25, 2009·Biochemical Pharmacology·Hervé SchaffhauserMichael J Marino
Jan 29, 2011·Pharmacological Reports : PR·Katarzyna FijałMałgorzata Filip
Jun 1, 2018·Expert Opinion on Investigational Drugs·Rita KhouryGeorge T Grossberg
Feb 23, 2012·Experimental Neurobiology·Hyung-Mun Yun, Hyewhon Rhim
Jan 31, 2009·The Journal of Comparative Neurology·Vanessa BernedoPedro Pesini
Apr 28, 2009·Journal of Neuroscience Research·Ellen S MitchellJohn F Neumaier
Jul 11, 2009·Expert Review of Neurotherapeutics·Werner J Geldenhuys, Cornelis J Van der Schyf
Sep 14, 2014·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Susanna TseR Scott Obach
Apr 24, 2013·Alzheimer's Research & Therapy·Maria J Ramirez
Oct 3, 2019·Expert Review of Neurotherapeutics·Matthew J BarrettKathryn L Holloway
May 7, 2015·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Gareth Maher-EdwardsMichael Gold
Apr 8, 2020·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Hugo Geerts, Athan Spiros
Feb 7, 2014·Reviews in the Neurosciences·Agnieszka Nikiforuk
Mar 14, 2014·Reviews in the Neurosciences·Anne QuiedevilleThomas Freret
Nov 22, 2013·Reviews in the Neurosciences·Alfredo Meneses
Aug 19, 2010·Expert Opinion on Therapeutic Patents·Alexandre V IvachtchenkoSergey E Tkachenko
Jul 24, 2012·Expert Opinion on Therapeutic Patents·Alexandre V Ivachtchenko, Yan A Ivanenkov


Oct 1, 1991·Journal of Neuroscience Methods·V R Roettger, M D Goldfinger
Dec 1, 1984·Naunyn-Schmiedeberg's Archives of Pharmacology·L BeaniE Veratti
May 28, 1993·Biochemical and Biophysical Research Communications·M RuatJ C Schwartz
Jan 12, 1999·British Journal of Pharmacology·A BoursonA J Sleight
Aug 8, 2001·Neuropharmacology·Marie L WoolleyK C F Fone
Oct 30, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Lee A DawsonP Li
Nov 10, 2001·Psychopharmacology·Derek Rogers, Jim J Hagan
Apr 3, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sudabeh Shirazi-SouthallGeorge G Nomikos
Jun 19, 2003·Drug News & Perspectives·Alfredo Meneses
Sep 17, 2003·The Journal of Pharmacology and Experimental Therapeutics·Mark D LindnerValentin K Gribkoff
Oct 23, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Andrew G FoleyCiaran M Regan
Feb 18, 2004·Current Drug Targets. CNS and Neurological Disorders·Marie L WoolleyK C F Fone

Related Concepts

Establishment and Maintenance of Localization
Monoclonal Antibodies
Cortex Bone Disorders
Adrenal Cortex Diseases
SCH 23390
Antagonist Muscle Action

Related Feeds

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.